Kamal Adawi, an officer of Fate Therapeutics Inc, filed a Form 144 notice on November 3, 2026, proposing the sale of 6,582 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ.

Key Highlights

  • Proposed sale: 6,582 shares of Fate Therapeutics common stock, with an aggregate market value of $13,524.69, according to the filing.
  • Source of shares: The shares were acquired on November 2, 2026, via restricted stock vesting from the issuer, classified as compensation.
  • Approximate sale date: November 3, 2026, to be executed through Fidelity Brokerage Services LLC.
  • Shares outstanding: 119,820,514 shares of common stock were reported outstanding at the time of the filing.
  • No prior sales: The filing reports nothing to disclose under sales of issuer securities during the past three months.
  • Purpose noted: The filing states the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."

Adawi's Proposed Share Sale Following Restricted Stock Vesting at Fate Therapeutics

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Kamal Adawi, identified as an officer of Fate Therapeutics Inc (NASDAQ:FATE), proposed to sell 6,582 shares of the company's common stock. The filing lists an aggregate market value of $13,524.69 for the proposed sale, with the approximate date of sale given as November 3, 2026.

The filing discloses that the shares to be sold were acquired on November 2, 2026, through restricted stock vesting from the issuer. The nature of payment is listed as compensation. As noted in the remarks section of the filing, the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution," a common practice associated with equity award settlements where a portion of vested shares is sold to satisfy applicable tax withholding requirements.

The proposed transaction is to be carried out through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917. The filing was signed by Joshua Schmitt as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Kamal M. Adawi. The filing reports no sales of Fate Therapeutics securities by Adawi during the three months preceding the notice date.

What Was Disclosed

Fate Therapeutics officer Kamal Adawi filed a Form 144 on November 3, 2026, disclosing a proposed sale of 6,582 shares of common stock valued at $13,524.69, acquired through restricted stock vesting the prior day, partly to cover tax obligations.